Inherited immune disorders
RAG1 deficiency
If you or someone you love has just heard this diagnosis, start here. This guide explains what the condition is, how it is usually treated and where a transplant fits.
RAG1 deficiency is a rare inherited immune disorder. The RAG1 gene is needed to build T and B cells, the white blood cells that recognize germs. Severe forms cause SCID or Omenn syndrome in babies, while milder forms can cause infections and autoimmune problems later in life. For the severe forms, a donor stem cell transplant is the treatment that can build a lasting immune system.
Other names and abbreviations
RAG1-SCID, T-B-NK+ SCID, Omenn syndrome, SCID, primary immunodeficiency, RAG1-associated severe combined immunodeficiency, Severe combined immunodeficiency due to complete RAG1 deficiency, Omenn syndrome due to RAG1 deficiency
In short
- RAG1 deficiency is an inherited immune disorder that can cause SCID, Omenn syndrome or later immune problems. Which one appears depends on how well the gene still works.
- Before transplant, care may include preventing and treating infections and antibody (immunoglobulin) support. It may also include treatment for inflammation or autoimmune problems.
- A stem cell transplant from a related or unrelated donor can provide working immune cells. Timing is based on each person's immune pattern, infections and organ health.
Jump to a section
Underlined words open a short explanation. See all terms
Where transplant fits
Allogeneic transplantationComing from another person. In an allogeneic, or donor, transplant, the stem cells come from a relative or an unrelated volunteer whose cells are a close enough match to the patient's. can provide functioning donor immune cells. A suitable related or unrelated donor may be used. The person’s actual immune phenotype, infections and organ health guide timing and conditioningTreatment that prepares a patient for a stem cell transplant. It can include chemotherapy, radiation or antibody medicines. It makes room in the marrow for the new cells, helps prevent rejection and can kill cancer cells..
Treatment depends on the exact diagnosis, disease stage, prior treatment and the person’s health.
Some patients need a donor who is not a relative.
See if you can joinKey facts
- Who it affects
- Can be identified in infancy or later childhood and adulthood, depending on the variants and remaining protein function.
- How common
- 8 of 52 babies found with SCID had RAG1 changes3,030,083 newborns screened in 10 U.S. states and the Navajo Nation, 2008–2013 (Kwan et al., JAMA 2014). SCID of all types was found in about 1 in 58,000 births. Four of the 8 had typical SCID and 4 had leaky SCID, including 1 with Omenn syndrome. Source: How common
- How it is passed on
- Autosomal recessive: a child is affected when both parents pass on a changed gene.
- Cells used in a transplant
- When transplantation is appropriate, the graft contains blood-forming stem cells from a suitable donor. Bone marrow, peripheral blood or cord blood may be selected according to the condition and transplant protocol.
- Where a donor fits
- Donor transplant option
The condition
What it is
Every T cellA type of white blood cell that is part of the immune system. T cells grow from stem cells in the bone marrow, help protect the body from infection and may help fight cancer. and B cellA type of white blood cell that makes antibodies. B cells are part of the immune system and grow from stem cells in the bone marrow. Some lymphomas and leukemias start in B cells. carries a receptor that fits one particular germ, like a key made for one lock. To make millions of different receptors, developing cells cut and rejoin pieces of their own DNA. The RAG1 protein, working as a pair with RAG2, makes those cuts. When RAG1 does not work, T and B cells cannot develop normally.
RAG1 deficiency is a range of illnesses, not a single one. When the protein does not work at all, a baby has SCID, with almost no T or B cells. When some activity remains, the result can be Omenn syndrome, “atypical” or “leaky” SCID, or a combined immune deficiency that appears later. Natural killer (NK) cells, another kind of infection-fighting white blood cell, are usually present in every form.
About these numbers. Each one says which group of people it comes from, and the place and years where the source gives them. It describes what happened across that group, not what will happen to any one person. And a figure measured among people who had a transplant is not the same as the number of people who need one.
- SCID 140; Omenn syndrome 155; atypical SCID 66; later-onset forms 68How RAG deficiency showed up in reported cases
429 people worldwide with RAG1 (303) or RAG2 (126) changes, reported in the medical literature or known to the authors of a review published in 2018. RAG1 and RAG2 are counted together. These are reported cases, not how common each form is.
Read the source: How RAG deficiency showed up in reported cases
Marked as affected: B cells and T cells.
- Blood stem cell, In the bone marrow
- Myeloid line
- Red blood cells
- Platelets
- Granulocytes
- Monocytes
- Lymphoid line
- B cells, Affected
- Plasma cells, Develop from B cells
- T cells, Affected
- NK cells, Natural killer cells
- Myeloid line
What causes it
The condition is caused by changes in both copies of the RAG1 gene. It is inherited in an autosomal recessive pattern: parents usually each carry one changed copy and have no symptoms. When both parents are carriersSomeone with one changed copy of a disease gene who has no symptoms or only mild ones. A carrier can pass the change to a child. A child with a changed copy from each parent usually has the condition., each pregnancy has a 1 in 4 chance of an affected child.
How much RAG1 activity is left helps explain how severe the illness is. Changes that leave no working protein tend to cause SCID, and changes that leave some activity tend to cause Omenn syndrome or milder, later forms. The link is not exact, and relatives with the same gene changes can be affected differently. RAG deficiency is more common in communities where parents are often related by blood.
- Parent: Carrier: one changed copy, not affected
- Parent: Carrier: one changed copy, not affected
- 1 in 4: Affected, Two changed copies
- 2 in 4: Carrier, One changed copy, like the parents
- 1 in 4: Neither affected nor a carrier, Two working copies
The chances are the same for each pregnancy.
Both copies of the RAG1 gene carry a change. Parents usually each carry one changed copy without showing signs of the condition.
- Changed copy of the gene
- Working copy
Symptoms and effects
Babies with RAG1 SCID usually look well at birth, then develop severe infections, ongoing diarrhea and poor growth in the first months. Omenn syndrome also starts in the first weeks of life, with a red rash over much of the body, hair loss, swollen lymph nodes and an enlarged liver and spleen. In Omenn syndrome, the child’s T cells are nearly all alike, and they attack the skin, gut and other organs. Live vaccines such as rotavirus and BCG can cause serious illness in these babies.
Milder forms can first appear later in childhood or even in adulthood. People may have repeated sinus and lung infections, and severe infections with herpes-family viruses such as chickenpox. Some have autoimmune problems, in which the immune system attacks blood cells or other organs. Some develop granulomas, clumps of inflamed immune cells in the skin, lungs or elsewhere. These forms are often diagnosed late, sometimes after organ damage has begun.
Where newborn screeningTests for serious conditions, often done before a newborn baby leaves the hospital. Some use a few drops of blood from the baby's heel. If a result points to a condition, more tests check for it. for SCID is offered, a heel-prick blood test can flag many babies with severe RAG1 deficiency before they get sick. The test looks for low levels of new T cells. A flagged result needs urgent follow-up with an immune specialist. Later-onset forms are usually recognized only after years of symptoms.
Diagnosis and treatment
How RAG1 deficiency is diagnosed
Newborn screening can flag many babies with severe RAG1 deficiency. Every U.S. state has screened for SCID since December 2018, with a heel-prick test for signs of new T cells. A low result leads to more blood tests. These count T cells, B cells and natural killer (NK) cells (flow cytometry). Babies with RAG1 SCID usually have almost no T or B cells, but NK cells are present. In Omenn syndrome, tests often also show high eosinophils, high IgE, and T cells that are nearly all alike.
A gene test confirms the cause by finding changes in both copies of RAG1. More than 200 disease-causing changes in RAG1 and RAG2 are known. About 7 in 10 change a single building block of the protein. The type and place of a change can hint at how severe the illness will be, but not always. Some research labs also measure how well the patient's RAG protein works, which helps explain the severity.
Milder, later-onset forms are harder to spot. They can start in later childhood or adulthood, often with infections, autoimmune problems or granulomas, and diagnosis is often delayed. In a small study at the U.S. National Institutes of Health (NIH), 12 of 13 people with partial RAG deficiency had RAG1 changes. Their middle (median) age at diagnosis was 17 years.
A flagged newborn screen means a baby needs more tests. It is not a diagnosis on its own.
How it is treated
For SCID, Omenn syndrome and atypical SCID caused by RAG1, a blood stem cell transplantA treatment that gives a patient healthy blood-forming stem cells through a vein. The cells travel to the bone marrow and replace faulty marrow or marrow damaged by treatment. They can come from the patient or a donor. is the treatment that can build a lasting immune system. Without one, these severe forms are fatal in early childhood. Results are best when the transplant happens early, before about 3.5 months of age and before serious infection.
RAG1 SCID raises a particular question about conditioning, the chemotherapy given before a transplant. The child’s own immature cells and NK cells can crowd out or reject donor cells. Transplants without chemotherapy have failed in up to about 1 in 4 cases, and immunity can fade years later. Some chemotherapy helps donor cells take hold and is considered essential in Omenn syndrome, but teams weigh that benefit against side effects in a very young baby.
For later-onset forms, treating infections and autoimmunity comes first. Whether and when to transplant is decided person by person, and the best approach is not yet settled. An early-stage trial led from the Netherlands has tested gene therapyTreatment that adds a new gene or restores the work of a faulty or missing one. For some inherited disorders, the patient's own blood-forming stem cells are changed in a lab and given back. It does not use a donor. with a baby’s own corrected stem cellsYoung cells that can grow into every type of blood cell: red cells that carry oxygen, white cells that fight infection and platelets that help blood clot. They are found in the bone marrow and the bloodstream.. It is for babies under 2 years old with RAG1 SCID who have no matched brother, sister or other family donor. In September 2026 its trial listing showed enrollment paused after a serious medical event in one patient, while doctors check whether the treatment caused it. It is not an approved treatment.
A transplant replaces the blood and immune system. It may not undo lung damage or other harm from earlier infections or autoimmunity.
Kinds of treatment described for RAG1 deficiency: supportive care, medicines (for some people) and a donor stem cell transplant.
After diagnosis, the options described here
Supportive care
Antibody replacement and medicines to prevent pneumonia and fungal infections protect a baby before transplant.
Medicines, For some people
Medicines that calm the immune system control the rash and gut inflammation of Omenn syndrome before transplant and treat autoimmunity in later forms.
Donor stem cell transplant
For SCID, Omenn syndrome and atypical SCID, a donor stem cell transplant is the treatment that can build a lasting immune system.
What a transplant involves
These are the kinds of treatment this page describes, not a plan. Which ones fit, in what order and whether they are combined differs from person to person.
When transplant specialists are usually consulted
U.S. consultation guidelines from NMDP and ASTCT list SCID and Omenn syndrome for a transplant consultation at diagnosis, or when newborn screening flags them. If a donor transplant may be needed, they also call for HLA typingA lab test that finds a person's tissue type (HLA markers). It starts with a blood draw or a cheek swab. Doctors compare a patient's results with those of relatives, registry donors and cord blood units. of the child and family, and a first search of the NMDP Registry, at diagnosis.
Read the guidanceWhat a transplant involves
- Step 1
: Finding a donor
Relatives are tested first to see whether their tissue type (HLA) matches. If none match, the team searches donor registries and cord blood banks.
- Step 2
: Conditioning
Chemotherapy, sometimes with radiation, prepares the body for the new cells.
- Step 3
: Transplant day, Day 0
The donor’s cells are given through a vein, like a transfusion.
- Step 4
: Engraftment
The new cells settle in the marrow and start making blood cells, usually within weeks.
- Step 5
: Recovery
The immune system rebuilds over months. The team watches for infection, graft-versus-host disease (donor immune cells attacking the body) and relapse.
Daily life and the donor’s role
Living with the condition
Before a transplant, care focuses on preventing infection. This usually means immunoglobulin, which is antibodiesA protein made by the immune system that sticks to one specific target, such as a germ. Some wrongly target the body's own tissues. Lab-made antibody medicines can target markers such as CD20 or CD38 on some cancer cells. from donated plasma, medicines to prevent pneumonia and fungal infections, and keeping the baby away from sick people and crowds. Children with Omenn syndrome often also need medicines that calm the immune system, to control the rash and gut inflammation before transplant.
A transplant in infancy usually means a long hospital stay, then months of close checkups and protection from germs at home. Doctors follow how well T and B cells recover. Some children need immunoglobulin for a long time if their B cells do not fully return.
People with later-onset forms may live for years with infections, lung damage and autoimmune disease before the cause is found. Their care often involves several specialists and careful balancing of medicines that calm the immune system against the risk of infection.
The donor’s role
Most children with severe RAG1 deficiency need blood-forming stem cells from another person. A brother or sister with a matching HLAMarkers on most cells that make up a person's tissue type. Doctors test a patient's and donor's HLA to see how well they match. The more markers they share, the better the chance the body accepts the donor's cells. type gives the best results. When there is no matched relative, doctors search the registries for a matched unrelated donor, or use a half-matchedHalf-matched. A haploidentical donor's tissue type (HLA) matches about half of the patient's. It may be a parent, child, brother or sister. Care teams may use one when a fully or closely matched donor is not available. (haploidentical) parent or cord bloodBlood collected from a newborn baby's umbilical cord after birth. It contains many blood-forming stem cells, so donated cord blood can be used for a stem cell transplant.. Siblings are also checked for the family’s gene change, not only for their HLA match.
Timing makes the search urgent. European transplant guidelines say a donor should be sought as soon as SCID is diagnosed. If an unrelated donor cannot be found in time, a half-matched family member or a cord blood unitOne donated collection of cord blood. If it holds enough blood-forming stem cells, it is frozen and stored until a patient needs it. It is listed on a registry so patients searching for a match can find it. is preferred.
Every registry volunteer adds to the pool a search draws from. Joining cannot promise a match for any one child, and the transplant team chooses the safest suitable donor available at the time.
Highlighted here: a relative, an unrelated volunteer and donated cord blood.
The person’s own cells
Autologous transplant, no donor
Collected from the person before treatment, then given back.
A relative
Donor transplant (allogeneic)
A brother or sister may be a full match. Parents and children can be half-matched donors.
An unrelated volunteer
Donor transplant (allogeneic)
Found through a donor registry.
Donated cord blood
Donor transplant (allogeneic)
Collected from a baby’s umbilical cord after birth and stored in a public bank.
Some patients rely on a volunteer donor they have never met. Joining your country’s registry could make you that person for someone.
Join the registryFinding a donor and the outlook
How a donor is found
When a transplant from a donor is planned, the team usually tests brothers and sisters first. Each full sibling has about a one in four chance of being a full match.
Most patients do not have a matched relative. In the words of NMDP, the U.S. registry, “75% of patients don’t have a fully matched donor in their own family.” The team then searches registries of volunteer donors around the world and banks of donated cord blood. In some transplants, a half-matched parent, child or sibling can also be the donor.
8 of 8
All eight markers match. Doctors call this a full match.
8 of 8: the donor matches the patient at all eight markers, two each for HLA-A, HLA-B, HLA-C and HLA-DRB1.
7 of 8
One marker differs. Some transplants use a donor like this.
7 of 8: the donor matches at seven of the eight markers. One HLA-C marker differs.
Half-matched
One set, inherited together from one parent, matches. The rest may or may not.
Half-matched: the donor matches the four markers the patient inherited from one parent. The other four may or may not match.
- Matches
- Differs
- May or may not match
- Top row: from one parent. Bottom row: from the other.
- DR means HLA-DRB1
Doctors can look at up to 12 HLA markers, and usually aim to match 8 to 10 of them. This drawing shows the 8 that transplant guidelines count, and it reads each one as simply matching or not.
Matching depends on inherited tissue markers called HLA, so a patient is most likely to match someone who shares their ancestry. Every person who joins makes the search a little more likely to succeed, especially for patients from groups that are underrepresented on registries.
Looking ahead
Outlook for RAG1 deficiency
Without a transplant, RAG1 SCID and Omenn syndrome are usually fatal in early childhood. MedlinePlus Genetics says untreated children with Omenn syndrome usually survive only until age 1 or 2. A transplant has made long-term survival possible for many of these children.
Timing is the biggest factor that families and teams can influence. In a large U.S. and Canadian study of SCID, children did better when they were transplanted before 3.5 months of age and without an active infection. Across that study, children with RAG1 or RAG2 changes tended to do somewhat worse than those with the most common type of SCID, but the difference may have been due to chance. For partial RAG deficiency, organ damage before transplant was one of the strongest signs of lower survival. In one worldwide study, all 8 people diagnosed through newborn screening or family history survived.
For teens and adults with later-onset forms, results are still being gathered. In the small NIH study, 13 people aged 4 to 46 had a transplant, most with gentler (reduced-intensityLower doses of chemotherapy or radiation given before a donor transplant. They do not wipe out the marrow but calm the immune system enough to accept donor cells. It may be an option for older or less healthy people.) chemotherapy. Twelve had RAG1 changes. An estimated 8 in 10 were alive two years later. These are group results and cannot predict what will happen to one person.
About these numbers. They describe groups of people, not what will happen to any one person.
- 87%Alive 5 years after transplant for SCID (all genetic types together)
268 children with typical or atypical SCID of any genetic type, transplanted 2010–2018 at Primary Immune Deficiency Treatment Consortium centers in the United States and Canada (published 2023). RAG1 or RAG2 changes caused 23% of cases in this period. This is not a RAG-only figure, and it describes transplanted children only.
Read the source: Alive 5 years after transplant for SCID (all genetic types together) - 67.5%Alive 4 years after transplant for partial RAG deficiency
60 people with partial (hypomorphic) RAG1 (46) or RAG2 (14) deficiency who did not have typical SCID or Omenn syndrome, first transplanted 2004–2019 at 31 centers in Europe, North America and Australia (EBMT/ESID Inborn Errors Working Party and PIDTC study, published 2023); median follow-up 39 months.
Read the source: Alive 4 years after transplant for partial RAG deficiency - 87% without organ damage; 55% with organ damageAlive 4 years after transplant, by organ damage before transplant
Same 60-person worldwide group with partial RAG1 or RAG2 deficiency, first transplanted 2004–2019 (EBMT/ESID Inborn Errors Working Party and PIDTC study, published 2023).
Read the source: Alive 4 years after transplant, by organ damage before transplant
Common questions
What is the difference between RAG1 SCID and Omenn syndrome?
Both come from changes in the RAG1 gene, but they differ in how much the protein still works. When RAG1 does not work at all, a baby has SCID, with almost no T or B cells. When some activity remains, a baby may have Omenn syndrome. The baby makes T cells, sometimes many, but they are nearly all alike. They attack the child's own skin, gut and other organs. This causes a red rash, hair loss, swollen lymph nodes, and high eosinophils and IgE. Both are treated with a donor stem cell transplant.
Does newborn screening find RAG1 deficiency?
It can find many babies with the severe forms. Every U.S. state has screened for SCID since December 2018 with a heel-prick test for signs of new T cells. In a study of more than 3 million U.S. newborns screened from 2008 to 2013, 8 babies with RAG1 changes were found. Four had typical SCID and 4 had leaky SCID, 1 of them with Omenn syndrome. Milder forms may not cause trouble until later. They are often recognized only after years of infections or autoimmune problems.
Can adults have RAG1 deficiency?
Yes. Partial RAG1 deficiency can first cause problems in later childhood or even adulthood. People may have repeated infections, severe viral infections, autoimmune disease or granulomas, and diagnosis is often delayed. At the U.S. National Institutes of Health, 13 people with partial RAG deficiency had a transplant, 12 of them with RAG1 changes. They were diagnosed between ages 3 and 43. Most had reduced-intensity chemotherapy, and an estimated 8 in 10 were alive two years later. It is a small study.
Is there gene therapy for RAG1 deficiency?
Not an approved one. A phase 1/2 trial led from the Netherlands has been testing gene therapy with a baby's own corrected stem cells. It is for babies under 2 with RAG1 SCID who have no matched brother, sister or other family donor. Its ClinicalTrials.gov listing, last updated in July 2026, shows recruitment on hold. This followed a serious medical event in one patient, while the team checks whether the treatment caused it. For now, a donor stem cell transplant remains the standard treatment.
What is the survival rate for RAG1 SCID?
There is no large RAG1-only figure. The outlook section on this page gives survival from a large study of children transplanted for SCID of all types in the U.S. and Canada. Across that study, which ran from 1982 to 2018, children with RAG1 or RAG2 changes tended to do somewhat worse than those with the most common type. That difference may have been due to chance. Early transplant, before infections set in, is linked to better results.
Why the details matter
Neither the gene name nor a lymphocyte count tells you, on its own, how severe the disease is.
For your next appointment
RAG1 deficiency
From the Jada Bascom Foundation disease library, jadabascomfoundation.org. Printed .
Questions to bring to your care team
- Does our child's RAG1 change cause SCID, Omenn syndrome or a milder form, and how sure are you?
- Have our other children been tested for the gene change and for an HLA match?
- How much conditioning chemotherapy do you plan, and why that amount?
- What is the status of the RAG1 gene therapy trial, and could our child ever qualify?
- What is the exact name of the diagnosis or subtype, and what does it mean for treatment?
- What is the goal of each treatment you are suggesting?
- Is a transplant being considered? Why now, or why not yet?
- What happens if a fully matched donor is not found?
- Where can our family find support during treatment?
A one-page list to take to the next appointment, with room for notes.
Supporting someone with a diagnosisSupport for patients and families
These independent organizations offer information and support. JBF is not affiliated with them.
- SCID Foundation Shares SCID information, hosts an online family community, and offers Path Forward Scholarships to U.S. families during SCID treatment.United States
- Immune Deficiency Foundation Explains SCID types, including RAG1 deficiency, and works to improve diagnosis, treatment and quality of life for people with primary immunodeficiency.United States
- International Patient Organisation for Primary Immunodeficiencies (IPOPI) International association of national patient groups for primary immunodeficiency, working to improve patients' lives and earlier diagnosis worldwide.Worldwide
Sources and further reading
- Omenn syndrome
MedlinePlus Genetics, US National Library of Medicine, Accessed 2026-09-05 - Guidelines for hematopoietic stem cell transplantation for inborn errors of immunity
EBMT / ESID Inborn Errors Working Party, 2021 - Inborn Errors of Immunity
EBMT Handbook, 2024-04-11 - Phase I/II Clinical Trial of Autologous Hematopoietic Stem Cell Gene Therapy in RAG1-Deficient Severe Combined Immunodeficiency (NCT04797260)
ClinicalTrials.gov, US National Library of Medicine, Status verified 2026-07; accessed 2026-09-24 - RAG Deficiency: Two Genes, Many Diseases
Journal of Clinical Immunology, 2018-07-25 - EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity
Bone Marrow Transplantation (EBMT / ESID Inborn Errors Working Party), 2021-07-05 - Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study
The Lancet (Primary Immune Deficiency Treatment Consortium), 2023-06-20 - Newborn screening
Immune Deficiency Foundation, Accessed 2026-09-24 - Join the registry
NMDP, Accessed 2026-09-24 - On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation
Biology of Blood and Marrow Transplantation, March 2016 - Stem Cell and Bone Marrow Transplants for Cancer
NCI, Accessed 2026-09-24 - Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR
NMDP / CIBMTR, Transplantation and Cellular Therapy, 2025 - What is HLA? HLA basics, typing and matching
NMDP, Accessed 2026-09-26 - Matching with a patient
NMDP, Accessed 2026-09-26 - Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States
JAMA (Kwan et al.), 2014-08-20 - Hypomorphic RAG deficiency: impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT
Blood (Schuetz et al., EBMT/ESID Inborn Errors Working Party and PIDTC), 2023-02-16 - Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide-based approach
Journal of Allergy and Clinical Immunology (NIH Clinical Center; Dimitrova, Kanakry et al.), 2026-02-28 - 2024 Recommended Timing for Transplant Consultation
NMDP and American Society for Transplantation and Cellular Therapy (ASTCT), 2024 - Severe combined immunodeficiency (SCID) treatment
NMDP, Accessed 2026-09-26
This information explains a condition and its treatments. It cannot diagnose an illness or recommend treatment for an individual. Your care team can explain how the evidence applies to you. Written and source-checked by the Jada Bascom Foundation. Each page lists the published sources it draws on.
Ways to help
Someone may be waiting for a match.
Some people with RAG1 deficiency are treated with a transplant from a donor. When no relative matches, that donor is often a stranger who joined a registry.
Join the registry
JBF points you to the official registry that serves your country. It explains who can join and what donation involves.
Help someone you love find a donor
If someone you love needs a donor, our family guide explains practical ways to help. A registration drive can add many potential donors at once, for them and for others.
Support this work
Gifts to the Jada Bascom Foundation support donor-awareness education like this page, community outreach, drive planning and referrals to official registries.
More in the library
Keep learning
Part of Severe combined immunodeficiency (SCID), a guide to how the subtypes fit together.

